ScripNuvation is transitioning into a commercial-stage biopharma with the launch of Ibtrozi (taletrectinib) for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), where it will compete agai
ScripRiding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com
ScripSpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round f
ScripAlready riding high with positive early data for its long-acting GLP-1 analog candidate MET-097i, Metsera grabbed attention again on June 9 with Phase I data for its amylin analog MET-233i, which prod